Zydus Lifesciences USFDA Approval For Genetic Drug:
Zydus Lifesciences, a leading pharmaceutical company, announced on Monday that it has been granted approval by the US Food and Drug Administration (USFDA) to launch a generic version of a medication used to lower triglycerides in the American market. In a regulatory filing, the company stated that it has received final approval to market Icosapent Ethyl Capsules in strengths of 0.5 g and 1 g.
These capsules are recommended as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The annual sales of Icosapent Ethyl Capsules in strengths of 0.5 g and 1 g were recorded at USD 1,316 million in the US, according to IQVIA data.
As of now, the company’s shares were trading slightly higher at Rs 518.80 per share on the Bombay Stock Exchange (BSE). Zydus Lifesciences’ latest accomplishment demonstrates its commitment to providing high-quality, cost-effective healthcare solutions to patients worldwide.
About Zydus Lifesciences:
Zydus Lifesciences Ltd, previously known as Cadila Healthcare Limited, is a multinational pharmaceutical corporation headquartered in Ahmedabad, India. The company specializes in the production of generic drugs and was listed at the 100th position on the 2020 Fortune India 500 list.
For More Latest News Click Here